MET and neoplasm: Three of the type 1 pRCC cell line models (UOK208, UOK337, and UOK345) demonstrated activating mutations of the MET gene, including the first cell line ever derived from a tumor excised from an HPRC patient (UOK345), and all cell lines demonstrated MET gain.